Abstract
During the COVID-19 pandemic, the World Health Organization (WHO) updated guidelines advising that a risk-assessment framework considering local epidemiology and health services capacity be used to determine if travel measures should be implemented. Data, analysis, and models are needed to support these updated WHO guidelines. In 2020 and 2021, the Canadian province of Newfoundland and Labrador (NL) implemented travel measures that affected most travelers, including non-residents of NL, and NL residents that work outside the province. We used multiple data sources to estimate the total travel volume arriving in NL before and during the pandemic. We found that during the pandemic, travel to NL decreased by 82%, and the percentage of travelers arriving from given origins changed with Québec decreasing from 14 to 4%, and Alberta increasing from 7 to 17%. We formulated an importation model including many epidemiological details, however, a less detailed statistical model considering the product of infection prevalence and travel volume for each Canadian province and the territories better predicted daily travel-related cases of Canadian origin (R2 = 0.55). We conclude that the accuracy of importation models are limited more by data availability, particularly travel-related case data, and data quality, particularly between-country differences in infection reporting, than by the complexity and details of importation models. Our results are evidence that will inform future risk-assessment frameworks to support travel measure implementation decisions during public health emergencies.
Competing Interest Statement
AH was a member of the Newfoundland and Labrador Predictive Analytics modelling team and previously received funding from the Newfoundland and Labrador Centre for Health Information.
Funding Statement
All authors were supported by funding from Mathematics for Public Health (560523-2020), the One Health Modelling Network for Emerging Infections (560520-2020), and by the Emerging Infectious Disease Modelling Consortium funded by the Natural Sciences and Engineering Council of Canada. AH and JA are supported by the Canadian Network for Modelling Infectious Diseases (560516-2020)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health Research Ethics Board of Newfoundland and Labrador gave ethical approval for this work (reference number 2021.013)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The text has been revised to better communicate findings, to place the results in the broader context of the existing literature, and to make clearer recommendations.
Data Availability
Data requiring ethics approval can be requested from the Newfoundland and Labrador Centre for Health Information. All publicly available data are archived online.
